Barclays’s SELLAS Life Sciences SLS Stock Holding History

Barclays’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$528K	Buy	35,783 +3,371	+10%	+$23.3K	﹤0.01%	3185
2026 Q1	$137K	Sell	32,412 -478,622	-94%	-$2.14M	﹤0.01%	3894
2025 Q4	$1.93M	Buy	511,034 +328,354	+180%	+$638K	﹤0.01%	2958
2025 Q3	$294K	Buy	182,680 +9,877	+6%	+$17.6K	﹤0.01%	4117
2025 Q2	$378K	Buy	+172,803	New	+$265K	﹤0.01%	3912
2019 Q4	–	Sell	-17	Closed	–	–	6767
2019 Q3	$0	Buy	+17	New	+$125	﹤0.01%	7088
2019 Q1	–	Sell	-2	Closed	–	–	7300
2018 Q4	$0	Buy	+2	New	+$155	﹤0.01%	7298
2018 Q2	–	Sell	-1	Closed	–	–	7250
2018 Q1	$0	Buy	+1	New	+$285	﹤0.01%	7305
2017 Q2	–	Sell	-8	Closed	-$7K	–	6899
2017 Q1	$7K	Buy	+8	New	+$13.2K	﹤0.01%	6196
2016 Q4	–	Hold	0	–	–	–	6488

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's SLS Position: Q2 2026 in Review

Barclays increased its SELLAS Life Sciences (SLS) stake by 10% in Q2 2026, buying an estimated $23.3K and bringing the position to 35,783 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #3185.

Barclays first reported a position in SLS in Q1 2017 and has held it in 9 quarters since. The position peaked at $1.93M in Q4 2025. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

Barclays held 35,783 shares of SELLAS Life Sciences worth $528K as of Q2 2026.
Barclays bought 3,371 SELLAS Life Sciences shares in Q2 2026, an estimated $23.3K.
SELLAS Life Sciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3185 holding.
Barclays first reported a position in SELLAS Life Sciences in Q1 2017 and has held it in 9 quarters since.
Barclays's SELLAS Life Sciences position peaked at $1.93M in Q4 2025.
193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.